ReviewTranslational lung cancer research2015
Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis.
Review in Translational lung cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis.BMC cancer · 2020Pooled it
- Article
- Increased PD-L1 Restricts Liver Injury in Nonalcoholic Fatty Liver Disease.Oxidative medicine and cellular longevity · 2022Article
- Synthesis and Preclinical Evaluation of aJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Article
- XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients.Frontiers in oncology · 2019Article
- Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.Cancer research · 2018Article
- Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.Therapeutic advances in respiratory disease · 2017Review
- Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.Cell death & disease · 2017Article
- PD-L1 serves as a double agent in separating GVL from GVHD.The Journal of clinical investigation · 2017Article
- PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load.Scientific reports · 2017Article
- Prognostic value of PDL1 expression in pancreatic cancer.Oncotarget · 2016Article
- Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.Annals of oncology : official journal of the European Society for Medical Oncology · 2016Article
- Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.Scientific reports · 2016Article
- A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.International journal of molecular sciences · 2016Review
- Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Anti-programmed death-1 (anti-PD1)/programmed death ligand-1 (PD-L1) therapeutic antibodies targeting regulatory pathways in T cells have recently shown to promising clinical effectiveness in several solid tumors by enhancing antitumor immune response. Immune checkpoint therapy has propelled therapeutic efforts opening a new field in cancer treatment. However, durable clinical response has been educed only in a fraction of patients, underlining the need to predictively select those patients most likely to respond, e.g., by detecting predictive biomarkers. Immunohistochemistry (IHC) detection of PD-L1 in tumor cells has been used in various trials of anti-PD-1/PD-L1 agents to try to select those patients most likely to respond. However, since there are different techniques and scoring systems, results have not been conclusive. Thus efforts are needed to develop standardized IHC assays as well as to explore additional biomarkers to evaluate and predict immune responses elicited by anti-PD-1/PD-L1 therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.